Gadi Lachman

Current Position

Title: Operating Partner at Linden Capital Partners; Board Member at PicnicHealth, Konovo, and TriNetX Previous Role: Founder, President & CEO of TriNetX (departed March 31, 2025) Location: Cambridge, Massachusetts

Professional Background

Gadi Lachman is an accomplished healthcare technology entrepreneur and executive with over 20 years of leadership experience in healthcare IT, life sciences, and clinical research infrastructure. He founded TriNetX in 2014, building it into a globally recognized real-world data platform connecting more than 250 million patient records across 19 countries and serving thousands of researchers worldwide. Under his leadership, TriNetX became a sustainable, profitable business recognized as a market leader in federated healthcare data networks, supporting clinical trial design, site selection, patient recruitment, and real-world evidence generation.

Before founding TriNetX, Lachman held senior leadership roles at prominent healthcare technology firms, including Senior Vice President of Physician Networks at Amwell (American Well), Chief Operating Officer at Eliza Corporation, and Vice President of Operations at TriZetto. His background combines deep expertise in healthcare information systems standardization, data governance, and scaling enterprise software solutions. He also served as an Associate in Investment Banking at Lehman Brothers and held the Chief Executive Officer role at a Kaplan subsidiary. Lachman brings military discipline and strategic thinking from his service as an officer in the Israeli Special Forces, which informs his methodical approach to organizational leadership and mission-driven execution.

Lachman's foundational education blends law, accounting, and business strategy. He holds a BA in Accounting and an LLB in Law from Tel Aviv University, and earned an MBA with High Distinction (Baker Scholar designation) from Harvard Business School. His transition from operational leadership at TriNetX, announced on January 9, 2025, positions him to continue contributing to healthcare innovation through board roles and advisory relationships. After departing on March 31, 2025, he joined Linden Capital Partners as an Operating Partner in September 2025 and has taken on board positions at PicnicHealth (September 2025) and Konovo (May 2025), while continuing as an advisor to Carlyle, TriNetX's majority investor.

Career Timeline

Education

• MBA with High Distinction (Baker Scholar), Harvard Business School
• LLB in Law, Tel Aviv University
• BA in Accounting, Tel Aviv University

Public Presence

Social Media

Note: Only publicly accessible profiles are documented. Twitter/X account appears inactive despite account creation.

Published Writings

• "Letter from Gadi Lachman, CEO of TriNetX - 2021 in Review" — TriNetX (2021)
• Various CEO letters and company communications throughout TriNetX tenure
• Contributed to real-world data industry discussions and healthcare innovation discourse

Public Speaking

• "Unlocking the Power of Real-World Data: A Conversation with Gadi Lachman" — Alantra podcast with Frederic Laurier (2023-2024)
• Episode 24: Gadi Lachman, President and CEO, TriNetX — "Few & Far Between" podcast on rare disease research
• HIStalk Interviews with Gadi Lachman, CEO, TriNetX (June 2020, August 2017)
• TriNetX Summit 2022 Opening Address (recorded and available)
• Multiple healthcare industry conference appearances and panel discussions on real-world data, clinical trials, and healthcare innovation

Communication Style

Tone: Measured, educational, institutional. Lachman projects confidence grounded in rigorous methodology rather than hype. He is measured in his speech, collaborative yet intellectually precise, avoiding sensationalism while positioning TriNetX as a thought leader.

Recurring themes: Real-world data as a catalyst for healthcare transformation and drug development acceleration; accessibility and democratization of complex health data; data quality and integrity as non-negotiable foundations for research credibility; systemic complexity in healthcare data standardization and interoperability; collective responsibility and partnership across global healthcare networks; advancing equity and diversity in clinical research; connecting the "right trial, for the right patient, at the right site."

Notable positions: Strong advocate for rigorous data governance and investment in data quality assurance (TriNetX invested $150M+ in global data quality infrastructure); positioned against expedience that compromises research integrity (referenced COVID-era retracted research as systemic validation failures, not individual blame); champion of inclusive clinical trial design through tools like the "Diversity Lens" to ensure research represents diverse populations; proponent of patient-centered solutions; supporter of direct-to-patient models for healthcare data capture (evident in PicnicHealth board role).

Lachman's communication reflects a disciplined, systems-thinking approach rooted in both his legal training and healthcare technology background. He addresses complex infrastructure challenges with respect for their difficulty rather than oversimplifying them. His language balances technical precision (discussing EHR data standardization, master ontologies, and data mapping frameworks) with accessibility for broader audiences, making sophisticated healthcare IT concepts understandable to non-technical stakeholders. In interviews and written communications, he demonstrates collaborative framing—emphasizing partnership between technology providers, healthcare organizations, researchers, and patients rather than positioning TriNetX as a superior technology provider. His 2021 CEO letter exemplifies his value-driven approach, with explicit references to TriNetX's philanthropic commitments to UNICEF, NORD (National Organization for Rare Disorders), and WCRF International, reinforcing alignment with the broader research mission beyond commercial success. His communication prioritizes transparency about both achievements and ongoing challenges in healthcare data ecosystems. He frames failures in global context (e.g., pandemic-era validation breakdowns) with empathy for researchers while maintaining commitment to rigorous standards. This approach reflects institutional and collaborative thinking characteristic of leaders embedded in academic partnerships and global health ecosystems.

Notable Achievements

• Founded and scaled TriNetX (2014–2025) into a global real-world data network connecting 250+ million patient records across 19 countries serving major pharmaceutical companies, healthcare organizations, and clinical research institutions
• Built TriNetX into a market leader in clinical trial support: analyzed 26,000+ protocols, identified 7,000+ clinical trial opportunities, and reduced study site identification time by 50%
• Created sustainable, profitable healthcare tech business during periods of high growth—a rare achievement in healthcare IT venture building
• Named EY Entrepreneur Of The Year 2020 New England Award finalist for innovation and impact in healthcare technology
• Pioneered investment in data quality and integrity: Led deployment of $150+ million in capital investment globally to ensure reliability of federated healthcare networks and established TriNetX's "master ontology" framework for healthcare data standardization
• Launched TriNetX Diversity Lens analytics to advance equity in clinical trial design, ensuring research cohorts represent populations they aim to treat
• Recognized on Fortune Impact 20 List (2023) for pioneering advancements in clinical trial diversity
• Secured Carlyle as majority investor while maintaining operational independence, positioning TriNetX for institutional growth and sustainable long-term development
• Established trusted global research infrastructure connecting hundreds of healthcare organizations with thousands of clinical researchers and life sciences companies across 19 countries

Key Relationships

• Board Roles: TriNetX (continuing post-CEO), PicnicHealth (appointed September 2025), Konovo (appointed May 2025)
• Operating Partner: Linden Capital Partners (healthcare-focused private equity; joined September 2025)
• Advisor: Carlyle Group (TriNetX majority investor); serves as strategic advisor post-CEO departure
• CEO Successor Support: Collaborated with Jeff Margolis (TriNetX Director, Executive Chairman) during CEO transition period
• Strategic Advisor: PicnicHealth, where he brings expertise in direct-to-patient healthcare data models
• Professional Partnerships: Established relationships with Johns Hopkins, Boston Children's Hospital, and hundreds of healthcare organizations globally across TriNetX network
• Harvard Business School Network: Baker Scholar alumnus with ongoing connections to HBS community
• Israeli Professional Networks: Background connecting to Israeli healthcare technology and entrepreneurial ecosystems

Information Availability Assessment

Overall Availability: HIGH

Gadi Lachman's professional career is extensively documented through:

• TriNetX corporate communications and press releases (11 years of company announcements and CEO letters)
• Healthcare industry publications (HIStalk, BioSpace, PharmiWeb, and other healthcare technology media)
• Board announcements from PicnicHealth (September 2025), Konovo (May 2025), and Linden Capital Partners (September 2025)
• Business press coverage (PR Newswire, Bloomberg, Yahoo Finance, BusinessWire)
• Professional networking platforms (LinkedIn profile with 500+ connections)
• Podcast and interview appearances (Alantra, HIStalk, "Few & Far Between" rare disease podcast)

Limited personal biographical information is available; professional focus dominates public records. His departure from TriNetX was widely announced and covered in industry and business media.

Contextual Notes

• Geographic/Cultural Background: Israeli-born executive with Israeli military background; based in Cambridge, Massachusetts (TriNetX headquarters). Background bridges Israeli and American healthcare technology ecosystems.
• Transition Status (as of February 2026): Officially departed TriNetX CEO role March 31, 2025 (~11 months prior). Actively engaged in board roles and strategic advisory through Linden Capital Partners, indicating ongoing commitment to healthcare innovation and leadership rather than industry exit.
• Current Focus Areas: Real-world data platforms, healthcare data governance, clinical trial innovation, direct-to-patient healthcare models, and strategic healthcare technology investment advisory.